Magenta Therapeutics (MGTA) Announces Proposed $60M Share Offering

Magenta Therapeutics, Inc. (NASDAQ: MGTA) announced that it has commenced an underwritten public offering of $60 million of its common stock. Magenta also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Magenta.

Goldman Sachs & Co. LLC and Cowen are acting as joint bookrunning managers for the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

Magenta intends to use the net proceeds of the offering to advance its clinical and earlier stage programs and for research and development, working capital and general corporate purposes.

You May Also Be Interested In

• Fed’s Waller open to September rate hold - if disinflation holds up
• Korn Ferry to Participate in the Goldman Sachs Communacopia + Technology Conference 2026
• Zscaler to cut 3% staff